scholarly journals What should be done in the event of simultaneous massive pulmonary embolism and myocardial infarction with ST elevation?

2015 ◽  
Author(s):  
Recep Akgedik
Keyword(s):  
Myocardial Infarction ◽  
Pulmonary Embolism ◽  
Massive Pulmonary Embolism ◽  
St Elevation

It's a ST-Elevation Myocardial Infarction (STEMI), or Is It? Massive Pulmonary Embolism Presenting as STEMI

2018 ◽  
Vol 55 (1) ◽  
pp. 125-127 ◽  
Author(s):  
Osama Dasa ◽  
Mohammed Ruzieh ◽  
Zaid Ammari ◽  
Mubbasher A. Syed ◽  
Kris R. Brickman ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Pulmonary Embolism ◽  
Massive Pulmonary Embolism ◽  
St Elevation Myocardial Infarction ◽  
St Elevation

Could advanced drug delivery systems be the future in cardiovascular revascularization medicine?

Vascular ◽  
2016 ◽  
Vol 25 (4) ◽  
pp. 447-448 ◽  
Author(s):  
Marco Zuin ◽  
Gianluca Rigatelli ◽  
Giuseppe Faggian ◽  
Roberto L’Erario ◽  
Mauro Chinaglia ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Pulmonary Embolism ◽  
Clinical Practice ◽  
Percutaneous Transluminal Coronary Angioplasty ◽  
Massive Pulmonary Embolism ◽  
Bleeding Events ◽  
Systemic Thrombolysis ◽  
Future Clinical Practice ◽  
Transluminal Coronary Angioplasty

Acute myocardial infarction, stroke and pulmonary embolism required a prompt revascularization to restore the normal blood flow as soon as possible. Fibrinolytic treatment has gradually become both dated and underused in the treatment of acute myocardial infarction, after the wide diffusion of cathlab and percutaneous transluminal coronary angioplasty. Conversely, the use of systemic thrombolysis remained a benchmark in the treatment of both ischemic stroke and massive pulmonary embolism. In daily clinical practice, the use of thrombolytic agents is often limited by absolute and/or relative contraindications and possible adverse events after the drug administration, as intracranial and/or extracranial bleeding events. To minimize these problems, during the last years, the introduction of nanotechnology in the field of cardiovascular revascularization medicine has created several fascinating results. In the present article, we describe these recent findings and their possible implications in future clinical practice.

Sign in / Sign up

Export Citation Format

Share Document